Adicet Bio, Inc. (NASDAQ:ACET – Get Free Report) was the recipient of a large drop in short interest in August. As of August 31st, there was short interest totalling 4,100,000 shares, a drop of 10.3% from the August 15th total of 4,570,000 shares. Based on an average daily trading volume, of 921,000 shares, the days-to-cover ratio is currently 4.5 days.
Adicet Bio Trading Down 2.7 %
Shares of ACET stock opened at $1.46 on Thursday. Adicet Bio has a fifty-two week low of $1.05 and a fifty-two week high of $3.77. The stock has a 50 day moving average price of $1.43 and a two-hundred day moving average price of $1.63.
Adicet Bio (NASDAQ:ACET – Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.03. On average, analysts predict that Adicet Bio will post -1.35 earnings per share for the current year.
Institutional Inflows and Outflows
Analyst Upgrades and Downgrades
Several brokerages have issued reports on ACET. HC Wainwright lowered Adicet Bio from a “buy” rating to a “neutral” rating in a research note on Wednesday, September 11th. Canaccord Genuity Group lowered their price objective on shares of Adicet Bio from $19.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday, September 11th. StockNews.com lowered shares of Adicet Bio from a “hold” rating to a “sell” rating in a report on Tuesday, September 10th. Finally, Wedbush reiterated an “outperform” rating and issued a $5.00 target price on shares of Adicet Bio in a research report on Tuesday, September 10th.
Read Our Latest Research Report on Adicet Bio
About Adicet Bio
Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.
Further Reading
- Five stocks we like better than Adicet Bio
- How to Find Undervalued Stocks
- How Much Can You Make in Stocks in One Month?
- High Flyers: 3 Natural Gas Stocks for March 2022
- This Is the Top Large-Cap Stock Insiders Are Buying
- Trading Halts Explained
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Receive News & Ratings for Adicet Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adicet Bio and related companies with MarketBeat.com's FREE daily email newsletter.